"This acquisition represents a significant addition to our product range and is completely in line with our strategy to become a leading provider of ophthalmic products. Our goal is to meet the needs of ophthalmologists in all major therapeutic classes so that we can be their daily partners, whatever their type of practice, and notably in ocular surgery," according to Laboratoires Thea COO Jean-Frederic Chibret. The agreement with Carl Zeiss Meditec includes the acquisition of the production site of Mydriasert(R) located in La Rochelle, France along with relevant staff. Mydriasert(R) is already commercialized in five European countries. Thanks to this agreement, Carl Zeiss Meditec will continue to concentrate on its core activities. Laboratoires Thea will develop sales through their subsidiaries and distributors.
Mydriasert(R) provides a genuine alternative to the mydriatic eye drops that are commonly used for mydriasis.
Mydriasert(R) allows one to obtain an effective and stable mydriasis with just one simple medical act which helps to avoid repeat installations of different mydriatic eye drops either for surgical procedures or diagnostic purposes.
In comparison to traditional mydriatic eye drops, Mydriasert(R) allows for fewer nursing procedures, this in turn helps to free up nursing time, reduce the risk of human errors and allows healthcare staff to spend more time with their patients. The insert contains neither preservatives nor solvents.
This device, shaped like an oblong tablet, is applied beneath the eyelid
and disperses both phenylephrin hydrochlorid and tropicamide, whose
mechanisms of action are synergistic. Indeed, the alpha-sym
|SOURCE Laboratoires Thea|
Copyright©2010 PR Newswire.
All rights reserved